Clinical trials: Scleroderma, Diffuse
Interstitial Lung Disease Due to Systemic Disease
Registry of Autoimmune Interstitial Lung Disease
Interstitial lung diseases (ILD) constitute a group of entities characterized by inflammation and/or fibrosis of the lung parenchyma.
- Trial name
- EPIMAR (NCT05365009)
- Testing
- Multidisciplinary aproach
- Where
- Argentina
- Volunteers
- 1,000 people
- Sponsor
- EPIMAR registry
Lung Diseases, Interstitial
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma
Systemic sclerosis (SSc, scleroderma) is a multisystem autoimmune rheumatic disease that causes inflammation, vascular damage and fibrosis. Besides involvement of skin, fibrosis also affects lung and heart.
- Trial name
- NCT01553981
- Testing
- Tadalafil
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
SSc-Systemic Sclerosis
Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD
Patients with ssc-ild receiving double immunosuppression with or without anti fibrotic tratment
- Trial name
- NCT07491523
- Testing
- Antifibrotic drugs (nidanib or pirfenidone), MMF Immunosuppression
- Where
- Greece
- Volunteers
- 35 people
- Sponsor
- University of Patras
Scleroderma
Elastography Ultrasound in Localized Scleroderma (Morphea) Study
Localized scleroderma (LS) is a skin disease that can cause complications such as disfigurement and limitation of mobility. Treatment for LS should be initiated early in the disease, as late-stage scleroderma does not respond…
- Trial name
- NCT06847750
- Testing
- Elastography Ultrasound, The Localized Scleroderma Quality of Life Instrument (LoSQI )
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Hospital for Sick Children
Scleroderma, Localized, Morphea
Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea
This is a randomized, blinded, and controlled trial to assess the efficacy and safety of UVA1 phototherapy in the treatment of active morphea in adults and children.
- Conditions
- Scleroderma, Localized, Morphea, Scleroderma, Circumscribed
- Trial name
- NCT01799174
- Testing
- UVA-1 Phototherapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Texas Southwestern Medical Center
Systemic Sclerosis
Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement
The purpose of this study is to verify effect and tolerability of imatinib on pulmonary and skin fibrosis in patients affected by systemic sclerosis.
- Trial name
- NCT00573326
- Testing
- Imatinib
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
Systemic Sclerosis, Fatigue
Apollo Device for Fatigue in Systemic Sclerosis
The purpose of this study is to learn about the effect of Apollo (a vibrating wearable about the side of an Apple Watch) on fatigue, Raynaud symptoms, depression, quality of life, and disease symptoms in patients with systemic…
- Conditions
- Systemic Sclerosis, Fatigue, Raynaud Phenomenon
- Trial name
- NCT04854850
- Testing
- Apollo
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Robyn T. Domsic, MD, MPH
CREST Syndrome, Peripheral Vascular Disease
Exparel as a Nerve Block for Severe Hand Pain
The purpose of this study is to investigate whether the use of the study drug (Exparel) is safe and effective for treating circulation problems and pain in the hand or fingers.
- Conditions
- CREST Syndrome, Peripheral Vascular Disease, Raynaud Disease, Scleroderma, Diffuse
- Trial name
- NCT02374320
- Testing
- liposomal bupivacaine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jose Soberon, MD
Scleroderma, Systemic Sclerosis
SPIN Self-Management Feasibility Trial
The Scleroderma Patient-centered Intervention Network (SPIN) is an organization established by researchers, health care providers, and people living with scleroderma (systemic sclerosis; SSc) from Canada, the United States…
- Trial name
- SPIN-SELF-F (NCT03914781)
- Testing
- SPIN-SELF Program
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Lady Davis Institute
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).
- Trial name
- NCT02260557
- Testing
- Selexipag
- Where
- 16 sites in France, Germany and 1 more
- Volunteers
- 74 people
- Sponsor
- Actelion
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Main purpose: To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID).
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, IgG4 Related Disease
- Trial name
- NCT06361745
- Testing
- T cell injection targeting CD19 chimeric antigen receptor
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
IgG4 Related Disease, Systemic Sclerosis (SSc)
Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
Immune-mediated inflammatory diseases (IMIDs) are systemic inflammatory disorders driven by dysregulated immune responses that can affect multiple organs, including the lungs.
- Trial name
- NCT07806045
- Testing
- nebulized human umbilical cord mesenchymal stromal cell-derived extracellular vesicles
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Qiubai Li
Autoimmune Diseases, Ulcerative Colitis
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
The most clinically meaningful way to discover new targets of T cells in autoimmune diseases is to study the tissues of patients with active autoimmune disease mediated organ inflammation.
- Conditions
- Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma
- Trial name
- NCT06587828
- Testing
- Companion blood samples with procedure
- Where
- 11 sites in United States
- Volunteers
- 238 people
- Sponsor
- TScan Therapeutics, Inc.
Systemic Sclerosis, Interstitial Lung Disease
Interstitial Lung Disease Trajectories in Patients With Systemic Sclerosis
Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. In patients with systemic sclerosis, interstitial lung disease (ILD) concerns almost 50 % of patients and…
- Trial name
- SCLEROPIDEVOL (NCT05345795)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Central Hospital, Nancy, France
Autoimmune Diseases, Connective Tissue Diseases
Study of Silicone-Associated Connective Tissue Diseases
This study will examine the possible relationship between silicone implants or injections and the connective tissue diseases scleroderma and myositis.
- Conditions
- Autoimmune Diseases, Connective Tissue Diseases, Scleroderma, Circumscribed, Scleroderma, Systemic
- Trial name
- NCT00001330
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Scleroderma
Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY
Digital ulcers (DUs) are an expression of the microangiopathy in patients with scleroderma (SSc). DUs lead to pain and impaired hand use. DUs remain a severe complication for many patients and effective therapy remains elusive.
- Trial name
- SEDUCE (NCT01295736)
- Testing
- Sildenafil
- Where
- 24 sites in France
- Volunteers
- 84 people
- Sponsor
- University Hospital, Lille
SCAD, Addison Disease
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
This case control study aims to determine whether spontaneous coronary artery dissection (SCAD) is associated with autoimmune diseases and to update the incidence of SCAD in a population-based cohort.
- Conditions
- SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome
- Trial name
- NCT03941184
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Mayo Clinic
Systemic Sclerosis
Small Bowel Motor Impairment in Scleroderma: Results of a Prospective 5-year Manometric Follow-up
Small bowel involvement is still recognized to be associated with great morbidity and mortality in SSc patients, leading particularly to malabsorption and intestinal pseudo-obstruction.
- Trial name
- NCT00213460
- Where
- France
- Sponsor
- University Hospital, Rouen
Systemic Scleroderma
Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis
This study is a single-center, single-arm, open-label, exploratory clinical trial. A total of 30 patients with diffuse cutaneous systemic sclerosis (dcSSc) will be enrolled.
- Trial name
- NCT07502105
- Testing
- Firsekibart injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
Scleroderma, Systemic, Digital Ulcer
Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
This study is performed to consider the safety and healing ability of diosmin in patients with systemic sclerosis (scleroderma) and open sores on their fingers (digital ulcers).
- Trial name
- NCT06256575
- Testing
- Diosmin
- Where
- 5 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Primus Pharmaceuticals